| The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. | |
| | |
MedLine Citation:
|
PMID: 19185668 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a matter of concern for the lay public and physicians. In order to discuss this subject openly, the National Institute of Public Health of Quebec (INSPQ) organized a scientific meeting on February 15, 2008, with targeted physicians delegated by their medical associations in the fields of general practice, obstetrics and gynaecology, rheumatology, orthopaedic surgery, physiatry and endocrinology. STUDY DESIGN: Participants reviewed the scientific literature using the study classification method according to the level of evidence, reviewed published guidelines of medical societies and organizations on the subject and reached a consensus position. This manuscript presents a review of the literature and describes the consensus position of the targeted medical associations. RESULTS: The consensus position adopted by all the targeted medical associations determined that DMPA was a cost-effective contraceptive option that must be considered in the light of the clinical situation and preference of each woman. Candidates for injectable contraception should be informed that the use of DMPA is associated with a slight decrease in bone mineral density (BMD), which is largely, if not completely, reversible. There should not be an absolute limit to the length of time that the DMPA contraceptive is used, regardless of the woman's age. Monitoring BMD is not recommended among users of DMPA for contraceptive purposes. Finally, the consensus statement declared that, although supplements of calcium and vitamin D are beneficial for skeletal health for women in general, such supplementation should not be recommended solely based on a woman's use of DMPA. CONCLUSION: Given the scientific evidences, DMPA use remains a valid contraceptive option for women. Its potential impact on BMD must be balanced against the significant individual, familial and social consequences of unintended pregnancy. |
| | |
Authors:
|
Edith R Guilbert; Jacques P Brown; Andrew M Kaunitz; Marie-Soleil Wagner; Jocelyn Bérubé; Louise Charbonneau; Diane Francoeur; Andrée Gilbert; François Gilbert; Geneviève Roy; Vyta Senikas; Robert Jacob; Réal Morin |
Related Documents
:
|
1995378 - When is it possible to meet the wish of a woman to terminate her labour by caesarean se... 15778138 - Acute forensic medical procedures used following a sexual assault among treatment-seeki... 8747068 - Are 'natural' twinning rates continuing to decline? 10319598 - Providing mifepristone-misoprostol medical abortion: the view from the clinic. 18952938 - Repurposing the clinical record: can an existing natural language processing system de-... 21991088 - Operative guidelines in burns emergencies in a battle environment. |
Publication Detail:
|
Type: Consensus Development Conference; Journal Article; Review Date: 2009-01-15 |
Journal Detail:
|
Title: Contraception Volume: 79 ISSN: 1879-0518 ISO Abbreviation: Contraception Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-02-02 Completed Date: 2009-05-14 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 0234361 Medline TA: Contraception Country: United States |
Other Details:
|
Languages: eng Pagination: 167-77 Citation Subset: IM |
Affiliation:
|
National Institute of Public Health of Quebec, Quebec, Canada. edith.guilbert@inspq.qc.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Density
/
drug effects* Canada / epidemiology Contraception / standards* Contraceptive Agents, Female / adverse effects* Delayed-Action Preparations Female Fractures, Bone / epidemiology Humans Medroxyprogesterone Acetate / adverse effects* Osteoporosis / epidemiology* Pregnancy Pregnancy Rate |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptive Agents, Female; 0/Delayed-Action Preparations; 71-58-9/Medroxyprogesterone Acetate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Imaging in pulsatile tinnitus.
Next Document: Contraceptive failure related to estimated cycle day of conception relative to the start of the last...